Entera Bio, Inc.

Entera Bio Announces Positive Updates on Oral Peptide Programs and Q3 2024 Financial Results

7 months ago

• Entera Bio's EB613, an oral PTH(1-34) tablet for post-menopausal women with osteoporosis, shows promising comparative pharmacological data presented at ASBMR 2024. • Topline results for the oral oxyntomodulin (OXM) tablet program, a GLP-1/glucagon agonist for obesity, demonstrate significant systemic exposure and glucose reduction. • Entera Bio is advancing its oral GLP-2 tablet for Short Bowel Syndrome and EB612 for hypoparathyroidism, both in collaboration with partners. • The company's cash and cash equivalents totaled $6.9 million as of September 30, 2024, expected to fund operations into the third quarter of 2025.

Entera Bio and OPKO Health Announce Positive PK/PD Results for Oral Oxyntomodulin for Obesity and Metabolic Disorders

8 months ago

• Entera Bio and OPKO Health reported positive pharmacokinetic/pharmacodynamic (PK/PD) results for their oral oxyntomodulin (OXM) tablet candidate targeting obesity and metabolic disorders. • In vivo studies in rodent and pig models demonstrated significant systemic exposure and favorable bioavailability of oral OXM following a single dose. • Oral OXM significantly reduced plasma glucose levels in rats post-glucose administration compared to placebo, indicating potential pharmacologic effect. • The companies plan to present the data at an upcoming clinical conference and advance the program toward IND-enabling efforts.